Testen der Verwendung der Immuntherapeutika Ipilimumab und Nivolumab plus Strahlentherapie im Vergleich zur üblichen Behandlung (Temozolomid und Strahlentherapie) bei neu diagnostiziertem MGMT unmethyliertem Glioblastom
Eine randomisierte offene Phase-II/III-Studie zu Ipilimumab und Nivolumab im Vergleich zu Temozolomid bei Patienten mit neu diagnostiziertem MGMT (Tumor-O-6-Methylguanin-DNA-Methyltransferase) unmethyliertem Glioblastom
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temozolomide, may not work as well for the treatment of tumors that have the unmethylated MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is possible that immune checkpoint inhibitors may work better at time of first diagnosis as opposed to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may lengthen the time without brain tumor returning or growing and may extend patients' life compared to usual treatment with radiation therapy and temozolomide.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs progression-free survival (PFS) versus adding temozolomide to radiotherapy in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. (Phase II) II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs overall survival (OS) versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation. (Phase III)
SECONDARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs PFS versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation for the phase III part of the study.
II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly increases the 2-year OS rate versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation.
III. To evaluate the safety of adding ipilimumab and nivolumab to radiotherapy via comparative frequency between arms of specific adverse events of interest and frequency summaries for all adverse event types.
IV. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on patient reported outcomes (PROs), as measured by the MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) in patients with newly diagnosed GBM without MGMT promoter methylation.
V. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on selected Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in patients with newly diagnosed GBM without MGMT promoter methylation.
VI. To evaluate the impact of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on neurocognitive function (NCF) in patients with newly diagnosed GBM without MGMT promoter methylation.
EXPLORATORY OBJECTIVES:
I. To explore biomarkers in pre-treatment archival tumor tissue that may predict efficacy of ipilimumab and nivolumab as measured by OS, PFS, and 2-year OS rate, such as but not limited to:
Ia. PDL1 expression; Ib. Mutational burden. II. To explore (in the two treatment separately) whether the MGMT protein expression correlates with clinical outcomes including OS, PFS, and 2-year OS rate.
III. To evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide orally (PO) daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain magnetic resonance imaging (MRI) throughout the trial.
ARM 2: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab intravenously (IV) over 90 minutes once every 4 weeks (Q4W) for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial.
After completion of study treatment, patients are followed up every 3 months for year 1, then every 4 months for year 2, and then every 6 months thereafter.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Anaheim, California, Vereinigte Staaten, 92806
- Kaiser Permanente-Anaheim
-
Auburn, California, Vereinigte Staaten, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, Vereinigte Staaten, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Concord, California, Vereinigte Staaten, 94520
- John Muir Medical Center-Concord
-
La Jolla, California, Vereinigte Staaten, 92093
- UC San Diego Moores Cancer Center
-
Loma Linda, California, Vereinigte Staaten, 92354
- Loma Linda University Medical Center
-
Los Angeles, California, Vereinigte Staaten, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Vereinigte Staaten, 90048
- Cedars Sinai Medical Center
-
Ontario, California, Vereinigte Staaten, 91761
- Kaiser Permanente-Ontario
-
Orange, California, Vereinigte Staaten, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Roseville, California, Vereinigte Staaten, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, Vereinigte Staaten, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Vereinigte Staaten, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Vereinigte Staaten, 95817
- University of California Davis Comprehensive Cancer Center
-
Torrance, California, Vereinigte Staaten, 90509
- Torrance Memorial Medical Center
-
Torrance, California, Vereinigte Staaten, 90505
- Torrance Memorial Physician Network - Cancer Care
-
Walnut Creek, California, Vereinigte Staaten, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Colorado Springs, Colorado, Vereinigte Staaten, 80907
- Penrose-Saint Francis Healthcare
-
Denver, Colorado, Vereinigte Staaten, 80210
- AdventHealth Porter
-
Littleton, Colorado, Vereinigte Staaten, 80122
- AdventHealth Littleton
-
Parker, Colorado, Vereinigte Staaten, 80138
- AdventHealth Parker
-
-
Connecticut
-
Hartford, Connecticut, Vereinigte Staaten, 06102
- Hartford Hospital
-
New Britain, Connecticut, Vereinigte Staaten, 06050
- The Hospital of Central Connecticut
-
-
Delaware
-
Lewes, Delaware, Vereinigte Staaten, 19958
- Beebe Medical Center
-
Millville, Delaware, Vereinigte Staaten, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Vereinigte Staaten, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Vereinigte Staaten, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Vereinigte Staaten, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Vereinigte Staaten, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Vereinigte Staaten, 19971
- Beebe Health Campus
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32207
- Baptist MD Anderson Cancer Center
-
Orlando, Florida, Vereinigte Staaten, 32803
- AdventHealth Orlando
-
-
Georgia
-
Augusta, Georgia, Vereinigte Staaten, 30912
- Augusta University Medical Center
-
Savannah, Georgia, Vereinigte Staaten, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Vereinigte Staaten, 31404
- Memorial Health University Medical Center
-
Thomasville, Georgia, Vereinigte Staaten, 31792
- Lewis Hall Singletary Oncology Center
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Vereinigte Staaten, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Vereinigte Staaten, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Vereinigte Staaten, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Vereinigte Staaten, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Island Urology
-
Kailua, Hawaii, Vereinigte Staaten, 96734
- Castle Medical Center
-
Lihue, Hawaii, Vereinigte Staaten, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Vereinigte Staaten, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, Vereinigte Staaten, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Vereinigte Staaten, 96701
- Queen's Cancer Center - Pearlridge
-
‘Aiea, Hawaii, Vereinigte Staaten, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Vereinigte Staaten, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Fruitland, Idaho, Vereinigte Staaten, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Vereinigte Staaten, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Vereinigte Staaten, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Vereinigte Staaten, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Vereinigte Staaten, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Vereinigte Staaten, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Vereinigte Staaten, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Northwestern University
-
Chicago, Illinois, Vereinigte Staaten, 60612
- University of Illinois
-
Danville, Illinois, Vereinigte Staaten, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Vereinigte Staaten, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Carle Physician Group-Effingham
-
Elmhurst, Illinois, Vereinigte Staaten, 60126
- Elmhurst Memorial Hospital
-
Eureka, Illinois, Vereinigte Staaten, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Vereinigte Staaten, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Vereinigte Staaten, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Vereinigte Staaten, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Vereinigte Staaten, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Vereinigte Staaten, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Vereinigte Staaten, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, Vereinigte Staaten, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Vereinigte Staaten, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Vereinigte Staaten, 61938
- Carle Physician Group-Mattoon/Charleston
-
Naperville, Illinois, Vereinigte Staaten, 60540
- Edward Hospital/Cancer Center
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Vereinigte Staaten, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Vereinigte Staaten, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Vereinigte Staaten, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Vereinigte Staaten, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Vereinigte Staaten, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Vereinigte Staaten, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Vereinigte Staaten, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Vereinigte Staaten, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, Vereinigte Staaten, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Springfield Clinic
-
Springfield, Illinois, Vereinigte Staaten, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Vereinigte Staaten, 61801
- Carle Cancer Center
-
Urbana, Illinois, Vereinigte Staaten, 61801
- The Carle Foundation Hospital
-
Warrenville, Illinois, Vereinigte Staaten, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Washington, Illinois, Vereinigte Staaten, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- IU Health Methodist Hospital
-
-
Iowa
-
Ames, Iowa, Vereinigte Staaten, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Vereinigte Staaten, 50010
- McFarland Clinic - Ames
-
Clive, Iowa, Vereinigte Staaten, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Vereinigte Staaten, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Vereinigte Staaten, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Vereinigte Staaten, 51503
- Methodist Jennie Edmundson Hospital
-
Creston, Iowa, Vereinigte Staaten, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Vereinigte Staaten, 50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Tulane University School of Medicine
-
New Orleans, Louisiana, Vereinigte Staaten, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Vereinigte Staaten, 04401
- Eastern Maine Medical Center
-
Bath, Maine, Vereinigte Staaten, 04530
- MaineHealth Coastal Cancer Treatment Center
-
Belfast, Maine, Vereinigte Staaten, 04915
- MaineHealth Waldo Hospital
-
Brewer, Maine, Vereinigte Staaten, 04412
- Lafayette Family Cancer Center-EMMC
-
Portland, Maine, Vereinigte Staaten, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Vereinigte Staaten, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Vereinigte Staaten, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Maine Medical Partners Neurology
-
Scarborough, Maine, Vereinigte Staaten, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Vereinigte Staaten, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bel Air, Maryland, Vereinigte Staaten, 21014
- UM Upper Chesapeake Medical Center
-
Columbia, Maryland, Vereinigte Staaten, 21044
- Central Maryland Radiation Oncology in Howard County
-
Glen Burnie, Maryland, Vereinigte Staaten, 21061
- UM Baltimore Washington Medical Center/Tate Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Vereinigte Staaten, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Vereinigte Staaten, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Vereinigte Staaten, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Vereinigte Staaten, 48236
- Henry Ford Health Saint John Hospital
-
Flint, Michigan, Vereinigte Staaten, 48503
- Hurley Medical Center
-
Flint, Michigan, Vereinigte Staaten, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Vereinigte Staaten, 49048
- Beacon Kalamazoo
-
Livonia, Michigan, Vereinigte Staaten, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Michigan Healthcare Professionals Pontiac
-
Royal Oak, Michigan, Vereinigte Staaten, 48073
- Corewell Health William Beaumont University Hospital
-
Saginaw, Michigan, Vereinigte Staaten, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Vereinigte Staaten, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Vereinigte Staaten, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, Vereinigte Staaten, 48085
- Corewell Health Beaumont Troy Hospital
-
Warren, Michigan, Vereinigte Staaten, 48093
- Henry Ford Health Warren Hospital
-
West Branch, Michigan, Vereinigte Staaten, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, Vereinigte Staaten, 49519
- University of Michigan Health - West
-
Ypsilanti, Michigan, Vereinigte Staaten, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, Vereinigte Staaten, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Vereinigte Staaten, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Vereinigte Staaten, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Vereinigte Staaten, 55433
- Mercy Hospital
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Vereinigte Staaten, 55432
- Unity Hospital
-
Maple Grove, Minnesota, Vereinigte Staaten, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Vereinigte Staaten, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Vereinigte Staaten, 55454
- Health Partners Inc
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Vereinigte Staaten, 55102
- United Hospital
-
Stillwater, Minnesota, Vereinigte Staaten, 55082
- Lakeview Hospital
-
-
Mississippi
-
Jackson, Mississippi, Vereinigte Staaten, 39216
- University of Mississippi Medical Center
-
Southhaven, Mississippi, Vereinigte Staaten, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63703
- Saint Francis Medical Center
-
-
Montana
-
Billings, Montana, Vereinigte Staaten, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Vereinigte Staaten, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, Vereinigte Staaten, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Vereinigte Staaten, 59901
- Logan Health Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Vereinigte Staaten, 68123
- Nebraska Medicine-Bellevue
-
Lincoln, Nebraska, Vereinigte Staaten, 68516
- Cancer Partners of Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Vereinigte Staaten, 68118
- Nebraska Medicine-Village Pointe
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Hackensack University Medical Center
-
Livingston, New Jersey, Vereinigte Staaten, 07039
- Saint Barnabas Medical Center
-
Morristown, New Jersey, Vereinigte Staaten, 07960
- Morristown Medical Center
-
Neptune City, New Jersey, Vereinigte Staaten, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Rutgers Cancer Institute of New Jersey
-
Pennington, New Jersey, Vereinigte Staaten, 08534
- Capital Health Medical Center-Hopewell
-
Summit, New Jersey, Vereinigte Staaten, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Vereinigte Staaten, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, Vereinigte Staaten, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Vereinigte Staaten, 14642
- University of Rochester
-
Syracuse, New York, Vereinigte Staaten, 13210
- State University of New York Upstate Medical University
-
West Islip, New York, Vereinigte Staaten, 11795
- Good Samaritan University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Vereinigte Staaten, 28210
- Atrium Health Pineville/LCI-Pineville
-
Concord, North Carolina, Vereinigte Staaten, 28025
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Bismarck, North Dakota, Vereinigte Staaten, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Vereinigte Staaten, 44304
- Summa Health System - Akron Campus
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Riverside Methodist Hospital
-
Dublin, Ohio, Vereinigte Staaten, 43016
- Dublin Methodist Hospital
-
-
Oklahoma
-
Lawton, Oklahoma, Vereinigte Staaten, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Vereinigte Staaten, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Vereinigte Staaten, 97015
- Providence Cancer Institute Clackamas Clinic
-
Gresham, Oregon, Vereinigte Staaten, 97030
- Legacy Mount Hood Medical Center
-
Newberg, Oregon, Vereinigte Staaten, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Vereinigte Staaten, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Vereinigte Staaten, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Vereinigte Staaten, 97225
- Providence Saint Vincent Medical Center
-
Portland, Oregon, Vereinigte Staaten, 97227
- Kaiser Permanente Northwest
-
Tualatin, Oregon, Vereinigte Staaten, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Broomall, Pennsylvania, Vereinigte Staaten, 19008
- Crozer-Keystone Regional Cancer Center at Broomall
-
Chadds Ford, Pennsylvania, Vereinigte Staaten, 19317
- Christiana Care Health System-Concord Health Center
-
Lancaster, Pennsylvania, Vereinigte Staaten, 17601
- Lancaster General Ann B Barshinger Cancer Institute
-
Lancaster, Pennsylvania, Vereinigte Staaten, 17602
- Lancaster General Hospital
-
Monroeville, Pennsylvania, Vereinigte Staaten, 15146
- Forbes Hospital
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- UPMC-Shadyside Hospital
-
West Reading, Pennsylvania, Vereinigte Staaten, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Vereinigte Staaten, 15090
- Wexford Health and Wellness Pavilion
-
-
South Carolina
-
Rock Hill, South Carolina, Vereinigte Staaten, 29730
- Rock Hill Radiation Therapy Center
-
-
South Dakota
-
Pierre, South Dakota, Vereinigte Staaten, 57501
- Avera Cancer Institute at Pierre
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Collierville, Tennessee, Vereinigte Staaten, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Memphis, Tennessee, Vereinigte Staaten, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- Memorial Hermann Texas Medical Center
-
San Antonio, Texas, Vereinigte Staaten, 78229
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
American Fork, Utah, Vereinigte Staaten, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, Vereinigte Staaten, 84720
- Sandra L Maxwell Cancer Center
-
Logan, Utah, Vereinigte Staaten, 84321
- Logan Regional Hospital
-
Murray, Utah, Vereinigte Staaten, 84107
- Intermountain Medical Center
-
Ogden, Utah, Vereinigte Staaten, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, Vereinigte Staaten, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, Vereinigte Staaten, 84065
- Riverton Hospital
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84143
- LDS Hospital
-
St. George, Utah, Vereinigte Staaten, 84770
- Saint George Regional Medical Center
-
-
Vermont
-
Berlin Corners, Vermont, Vereinigte Staaten, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, Vereinigte Staaten, 05401
- University of Vermont Medical Center
-
Burlington, Vermont, Vereinigte Staaten, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Inova Schar Cancer Institute
-
Richmond, Virginia, Vereinigte Staaten, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, Vereinigte Staaten, 23970
- VCU Community Memorial Health Center
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98101
- Virginia Mason Medical Center
-
Vancouver, Washington, Vereinigte Staaten, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Vereinigte Staaten, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
-
West Virginia
-
Wheeling, West Virginia, Vereinigte Staaten, 26003
- Wheeling Hospital/Schiffler Cancer Center
-
-
Wisconsin
-
Burlington, Wisconsin, Vereinigte Staaten, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Germantown, Wisconsin, Vereinigte Staaten, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Vereinigte Staaten, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Vereinigte Staaten, 54311
- Aurora BayCare Medical Center
-
Johnson Creek, Wisconsin, Vereinigte Staaten, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
Kenosha, Wisconsin, Vereinigte Staaten, 53142
- Aurora Cancer Care-Kenosha South
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Vereinigte Staaten, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Vereinigte Staaten, 54548
- Marshfield Medical Center - Minocqua
-
New Richmond, Wisconsin, Vereinigte Staaten, 54017
- Cancer Center of Western Wisconsin
-
Oshkosh, Wisconsin, Vereinigte Staaten, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Vereinigte Staaten, 53406
- Aurora Cancer Care-Racine
-
Sheboygan, Wisconsin, Vereinigte Staaten, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Vereinigte Staaten, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Vereinigte Staaten, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wauwatosa, Wisconsin, Vereinigte Staaten, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Vereinigte Staaten, 53227
- Aurora West Allis Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
PRIOR TO STEP 1 REGISTRATION:
-
No known IDH mutation. (If tested before step 1 registration, patients known to have IDH mutation in the tumor on local or other testing are ineligible and should not be registered)
-
Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block and hematoxylin & eosin (H&E) stained slide to be sent for central pathology review for confirmation of histology and MGMT promoter methylation status. Note that tissue for central pathology review and central MGMT assessment must be received by the New York University (NYU) Center for Biospecimen Research and Development (CBRD) on or before postoperative calendar day 23. If tissue cannot be received by postoperative calendar day 23, then patients may NOT enroll on this trial as central pathology review will not be complete in time for the patient to start treatment no later than 6 weeks following surgery. Results of central pathology review and central MGMT analysis will generally be conveyed to NRG Oncology within 10 business days of receipt of tissue. Note: In the event of an additional tumor resection(s), tissue must be received within 23 days of the most recent resection and the latest resection must have been performed within 30 days after the initial resection. Surgical resection (partial or complete) is required; a limited biopsy is not allowed because it will not provide sufficient tissue for MGMT analysis
- Note: The central pathology review and central MGMT results determine eligibility. Therefore, patients may be offered the opportunity to consent REGARDLESS of local pathology and MGMT results, and consent can occur BEFORE local pathology interpretation is finalized and BEFORE local MGMT testing is conducted
-
Contrast-enhanced brain MRI within 3 days after surgery
- MRI with Axial T2 weighted FLAIR {preferred} or T2 turbo spin echo (TSE)/fast spin echo (FSE) and 3-dimensional (3D) contrast-enhanced T1 sequences are required
- 3D pre contrast-enhanced T1 sequences are strongly suggested
-
Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must be willing to use an adequate method of contraception hormonal or barrier method of birth control; or abstinence during and after treatment
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
-
PRIOR TO STEP 2 REGISTRATION:
-
Histopathologically proven diagnosis of glioblastoma (or gliosarcoma as a subtype of glioblastoma) confirmed by central pathology review
- Note: diagnoses of "Molecular glioblastoma" per the Consortium to Inform Molecular and Practical Approaches to Central Nervous System (CNS) Tumor Taxonomy (c-IMPACT-NOW) criteria or "CNS grade 4" per the World Health Organization (WHO) 2021 criteria are NOT relevant
-
MGMT promoter without methylation confirmed by central pathology review. Note: Patients with tissue that is insufficient or inadequate for analysis, fails MGMT testing, or has indeterminate or methylated MGMT promoter are excluded.
- Note: central pathology review and central MGMT results determine eligibility; local pathology or MGMT results cannot be used for eligibility/randomization
- Note: patients with methylated MGMT may be considered for enrollment on NRG-BN011
-
IDH mutation testing by at least one method (such as immunohistochemistry for IDH1 R132H) must be performed as part of standard of care and no mutation must be found (i.e IDH wildtype). (If a mutation is identified then the patient will be ineligible and must be registered as ineligible at step 2.)
- Note: this test is not being performed in real time as part of central review and will not be provided to sites from a centrally performed test
-
History/physical examination within 28 days prior to step 2 registration
-
Karnofsky Performance Status (KPS) >= 70 within 28 days prior to step 2 registration
-
Neurologic function assessment within 28 days prior to step 2 registration
-
Age >= 18 years
-
Hemoglobin >= 10 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) (within 7 days prior to step 2 registration)
-
Leukocytes >= 2,000/mm^3 (within 7 days prior to step 2 registration)
-
Absolute neutrophil count >= 1,500/mm^3 (within 7 days prior to step 2 registration)
-
Platelets >= 100,000/mm^3 (within 7 days prior to step 2 registration)
-
Total bilirubin =< 1.5 x institutional/lab upper limit of normal (ULN) (within 7 days prior to step 2 registration)
-
Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Alanine transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula) (within 7 days prior to step 2 registration)
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
For women of childbearing potential (WOCBP), negative serum or urine pregnancy test within 7 days prior to step 2 registration. Note that it may need to be repeated if not also within 3 days prior to treatment start
- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes
Exclusion Criteria:
-
Prior therapy for tumor except for resection. For example, prior chemotherapy, immunotherapy, or targeted therapy for GBM or lower grade glioma is disallowed (including but not limited to temozolomide, lomustine, bevacizumab, any viral therapy, ipilimumab or other CTLA-4 antibody, PD-1 antibody, CD-137 agonist, CD40 antibody, PDL-1 or 2 antibody, vaccine therapy, polio or similar viral injection as treatment for the tumor, and/or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) as is prior Laser interstitial thermal therapy (LITT), Gliadel wafer, radiotherapy, radiosurgery, gamma knife, cyber knife, vaccine or other immunotherapy, brachytherapy, or convection enhanced delivery;
- Note that 5-aminolevulinic acid (ALA)-mediated fluorescent guided resection (FGR) photodynamic therapy (PDT) or fluorescein administered prior to/during surgery to aid resection is not exclusionary and is not considered a chemotherapy or intracerebral agent
-
Current or planned treatment with any other investigational agents for the study cancer
-
Definitive clinical or radiologic evidence of metastatic disease outside the brain
-
Prior invasive malignancy (except non-melanomatous skin cancer, cervical cancer in situ and melanoma in situ) unless disease free for a minimum of 2 years
-
Prior radiotherapy to the head or neck that would result in overlap of radiation therapy fields
-
Pregnancy and nursing females due to the potential teratogenic effects and potential risk for adverse events in nursing infants
-
History of severe hypersensitivity reaction to any monoclonal antibody
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or temozolomide
-
On any dose of any systemically administered (oral, rectal, intravenous) corticosteroid within 3 days prior to step 2 registration. Inhaled, topical, and ocular corticosteroids are allowed without limitation but must be recorded. Note that treatment with systemically administered corticosteroid after initiating study treatment is allowed as needed
-
Patients with known immune impairment who may be unable to respond to anti-CTLA 4 antibody
-
History of interstitial lung disease including but not limited to sarcoidosis or pneumonitis
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, defined as New York Heart Association functional classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, are excluded, as are patients on active immunosuppressive therapy. These include but are not limited to: patients with a history of immune-related neurologic disease, CNS or motor neuropathy, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as autoimmune vasculitis [e.g., Wegener's Granulomatosis]), systemic lupus erythematosus (SLE), connective tissue diseases (e.g., systemic progressive sclerosis), scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome, Hashimoto's thyroiditis, autoimmune hepatitis are excluded because of the risk of recurrence or exacerbation of disease
-
Exceptions: patients with a history of the following conditions are not excluded, unless receiving active immunosuppressive therapy:
-
Vitiligo
-
Type I diabetes
-
Rheumatoid arthritis and other arthropathies
-
Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA)
- Anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
-
-
-
Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation are also excluded
-
Current or planned therapy with warfarin
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Arm I (radiation therapy, temozolomide)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide PO daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
Andere Namen:
Ancillary studies Given PO
Andere Namen:
Undergo radiation therapy
Andere Namen:
Undergo contrast-enhanced brain MRI
Andere Namen:
Wear Optune device
Andere Namen:
|
|
Experimental: Arm II (radiation therapy, ipilimumab, nivolumab)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab IV over 90 minutes Q4W for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
Andere Namen:
Given IV
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Undergo radiation therapy
Andere Namen:
Undergo contrast-enhanced brain MRI
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-free Survival (PFS) (Phase II)
Zeitfenster: From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
|
Overall Survival (OS) (Phase III)
Zeitfenster: From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PFS for the Entire Cohort (Phase II/III)
Zeitfenster: From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Overall Survival at 2 Years
Zeitfenster: From randomization to two years
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Two-year survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to two years
|
|
Number of Participants by Highest Grade Adverse Event Reported
Zeitfenster: From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Change in MD Anderson Symptom Inventory for Brain Tumor (MDASI-BT) Symptom Severity at Six Months (Patient Reported Outcomes)
Zeitfenster: Baseline and six months
|
The MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Symptom Severity subscale is a patient-reported outcome measure that assesses the severity of symptoms experienced by patients with brain tumors over the previous 24 hours. Possible subscale scores range from 0 to 10, with higher scores indicating a worse outcome. The change score was calculated as the 6-month value minus the baseline value. A negative change reflects improvement at 6 months and a positive change reflects decline at 6 months. |
Baseline and six months
|
|
Time to Neurocognitive Failure
Zeitfenster: From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
Neurocognitive failure is defined as the first instance of neurocognitive decline in any of six assessments, as determined by the reliable change index: Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Trail Making Test (TMT) part A, TMT part B, and Controlled Oral Word Association (COWA). Failure time is defined as time from randomization to failure, disease progression or death (competing events), or last follow-up (censored). Neurocognitive failure rates and median failure times are estimated using the cumulative incidence method. Participants with no baseline or no follow-up neurocognitive function data were censored at day 1. |
From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
|
Number of Participants With Most Severe Response for Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 6 Months
Zeitfenster: Six months
|
Questions refer to the participants' experiences for the past 7 days of a given symptom in terms of frequency (never, rarely, occasionally, frequently, almost constantly), severity (none, mild, moderate, severe, very severe), interference with usual or daily activities (not at all, a little bit, somewhat, quite a bit, very much). The last response of each of the lists is the most severe response. |
Six months
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
OS (wenn die Studie in Phase II abgebrochen wird)
Zeitfenster: Am Ende der Studienphase II
|
Am Ende der Studienphase II
|
|
|
Tumor Biomarker Analyses
Zeitfenster: Up to 4 years
|
Will assess PD-L1 expression and mutational burden expression specifically. |
Up to 4 years
|
|
MGMT Protein Expression
Zeitfenster: Up to 4 years
|
Will assess the prognostic value of MGMT protein expression (in terms of predicting clinical outcomes such as PFS, OS, and 2-year OS rate) in the two treatment arms, separately. In addition, will evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms. Correlation methods and survival modeling will be used to address these questions. |
Up to 4 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Andrew B Lassman, NRG Oncology
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Woroniecka K, Fecci PE. Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma. Neuro Oncol. 2020 Sep 29;22(9):1233-1234. doi: 10.1093/neuonc/noaa170. No abstract available.
- Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl M, Galbraith K, Dignam JJ, Won M, Mehta MP. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 Sep 20;43(27):3032-3040. doi: 10.1200/JCO-25-00618. Epub 2025 Aug 8.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Neubildungen nach histologischem Typ
- Neubildungen, Drüsen und Epithelien
- Gliom
- Neubildungen, Neuroepithel
- Neuroektodermale Tumoren
- Neoplasmen, Keimzelle und Embryonal
- Neubildungen, Nervengewebe
- Gliosarkom
- Aminosäuren, Peptide und Proteine
- Proteine
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Untersuchungstechniken
- Therapeutika
- Azolen
- Pharmakologische Maßnahmen
- Chemische Handlungen und Verwendung
- Biologische Faktoren
- Physikalische Phänomene
- Dacarbazin
- Triazenes
- Imidazoles
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Spezialzwecke von Chemikalien
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Rezeptoren, Zelloberfläche
- Membranproteine
- Antigene
- Antigene, Oberfläche
- Biomarker
- Diagnostische Anwendungen von Chemikalien
- Rezeptoren, immunologisch
- Antigene, Differenzierung, T-Lymphozyten
- Antigene, Differenzierung
- Immun -Checkpoint -Proteine
- Kostimulierende und inhibitorische T-Zell-Rezeptoren
- Temozolomid
- Nivolumab
- Ipilimumab
- Strahlentherapie
- Strahlung
- Magnetresonanzspektroskopie
- Kontrastmedien
- CTLA-4-Antigen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NCI-2020-03404
- U10CA180868 (US NIH Stipendium/Vertrag)
- NCI-2020-03404 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- NRG-BN007 (Andere Kennung: CTEP)
- NRG-BN007 (Andere Kennung: NRG Oncology)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .